Autism is a neurodevelopmental disorder, diagnosed behaviorally by social and communication deficits, repetitive behaviors, and restricted interests. Recent genome-wide exome sequencing has revealed extensive overlap in risk genes for autism and for cancer. Understanding the genetic commonalities of autism(s) and cancer(s), with a focus on mechanistic pathways, could lead to repurposed therapeutics.
Autism is a neurodevelopmental disorder, diagnosed by behavioral symptoms including impaired social interactions and communication, repetitive behaviors, and restricted interests [1] . Extraordinarily high heritability for autism spectrum disorder (ASD) has been detected in twin studies, with a range of 50-90% concordance between monozygotic twins, compared with 0-30% between dizygotic twins and siblings, and approximately 1% prevalence in the general population, along with a high male:female ratio [2] . International consortia searching for the genetic causes of ASD quickly recognized that autism is not a monogenic disorder. Hundreds of de novo and familial risk genes, copy number variants, and epigenetic modifiers have been identified through linkage analysis, genome wide-association studies, and exon and whole-genome sequencing of individuals with ASD over the past 2 years [2] [3] [4] [5] . Table 1 summarizes the characteristics of risk genes for ASD that are also risk genes for cancers, extending the original finding that the PI3K-Akt-mTOR signaling axis (involving PTEN, FMR1, NF1, TSC1, and TSC2) was associated with inherited risk for both cancer and ASD [6] [7] [8] [9] . Recent genome-wide exome-sequencing studies of de novo variants in ASD and cancer have begun to uncover considerable additional overlap. What is surprising about the genes in Table 1 is not necessarily the number of risk genes found in both autism and cancer, but the shared functions of genes in chromatin remodeling and genome maintenance, transcription factors, and signal transduction pathways leading to nuclear changes [7, 8] . Chromatin remodeling factors important in altering nucleosome accessibility for transcription and genome maintenance mechanisms include CHD8, CHD7, CHD2, ARID1B, and ATRX. ATRX may exert a more specific function in telomere maintenance, analogous to other Swi2/Snf2 family factors, such as ERCC6, RAD54, HTLF, SHPRH, or RAD16, which function in dedicated DNA repair pathways. Proteins involved in histone methyltransferase reactions important in setting the histone code include ASHL1, EHMT1, EHMT2, KMT2C, KMT2D, and SUV420H1. PHF2, KDM5B, and KDM6B are histone demethylases, and MACROD2 encodes a nuclear factor regulated by a metabolite of histone deacetylation. Ubiquitin modifications to histones and other proteins are implicated by the risk genes CUL3, HERC2, MIB1, TBL1XR1, TRIP12, UBE3A, and WAC. Transcription factors genetically implicated in both autism and cancer include ADNP, PAX5, FOXP1, TCF7L2, and TBLXR1. Interestingly, these nuclear factors are downstream of several key signal transduction pathways also genetically implicated in ASD and cancer, including PTEN [7] . PTEN functions in the AKT signaling pathway, where its phosphatase activity is needed for AKT downregulation. Nuclear PTEN also regulates recombinational DNA repair, a key genome maintenance pathway (see below). It is unclear whether this is related to its signaling function or a consequence of a second independent PTEN activity, but this dual function may provide the rationale for the dominant role of PTEN in cancer and autism. Other genes encoding common tumor signaling pathways include
, and HRAS, while p53, AKT, mTOR, WNT, NOTCH, and MAPK are components of signaling pathways regulating the nuclear factors described above.
Autism is comorbid with several monogenic neurodevelopmental disorders, including Fragile X (FMR1), Rett syndrome (MECP2), Phelan-McDermid (SHANK3), 15q duplication syndrome (UBE3A), neurofibromatosis (NF1), tuberous sclerosis (TSC1 and TSC2), and Cornelia de Lange syndrome (NIPBL and SMC1A) ( Table 1 ). Neurofibromatosis and tuberous sclerosis are directly associated with tumors, but such tumors are benign and rarely associated, if at all, with malignancies. However, mutations in NF1, TSC1, or TSC2 enhance the risk for developing cancer [6] . Notably, NF1, TSC1, and TSC2 function like PTEN in the AKT pathway of mTOR control. Mutations in transcriptional factor genes also mediate downstream signaling pathways that include key proteins implicated in cell proliferation or differentiation pathways implicated in cancer and autism, such as mTOR, RAS GTPases, MAP kinases, AKT, EIF4E, WNT, ERK, PI3K, and CHD8. A risk gene originally identified in individuals with cancer may present as a de novo mutation in a small number of individuals with ASD, or may be implicated in ASD through interactome analysis of interrelated genes and interacting proteins, such as within a signaling pathway (Table 1) .
What does tumor cell proliferation have in common with brain development and neuronal synapse formation? Similar to cancers, 'autisms' are best conceptualized in the plural. ASD encompasses a broad range of putative causes, symptom presentations, and outcomes, including The functional overlap of genes and pathways between autism and cancer would suggest that individuals with autism carry a higher cancer risk. While there is some epidemiological evidence of higher cancer risk in children, adolescents, and young adults with ASD [9, 12] , the absolute number of cases is low and more studies need to be conducted, particularly in adults, because cancer incidence is significantly correlated with age.
Mouse models with mutations in many of these genes have been widely used in both cancer and autism research. Some of these mutant mouse models recapitulate behavioral and biological features of autism [13] . These model systems are proving useful in understanding the consequences of specific mutations on overgrowth of brain regions, unusual patterns of white matter connectivity, aberrant numbers of synapses, and altered morphology of dendritic spines, in parallel to understanding cell proliferation, cell cycle, DNA repair, and epigenetic causes in malignancies. 
